CSPC Pharmaceutical Group (HK:1093) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CSPC Pharmaceutical Group Limited has announced a lucrative exclusive licensing agreement with AstraZeneca to develop and market their novel Lipoprotein(a) inhibitor compound, YS2302018. The deal includes an initial $100 million payment to CSPC, with the potential for up to $370 million in development milestones and up to $1.55 billion in sales milestones, plus sales royalties. The AI-developed compound shows promise in pre-clinical studies for reducing cardiovascular risk by targeting and inhibiting Lp(a) formation.
For further insights into HK:1093 stock, check out TipRanks’ Stock Analysis page.